[Effect of tetrandrine combined with Droloxifen on the expression of bcr/abl of K562 at both mRNA and protein levels].
To observe the effect of Tetrandrine (tet) combined with Droloxifen (DRL) on the expression of bcr/abl mRNA and P(210) BCR/ABL protein of K562 cell line, after K562 cells were cultured in the medium containing Tet (1 micromol/L), DRL (5 micromol/L) separately or in their combination for some time, the changes of bcr/abl mRNA and protein expression were detected by RT-PCR and Western blot respectively. The results showed that the application of single drug of Tet or DRL had no effect on bcr/abl mRNA and BCR/ABL protein expression in K562 cell line. However, Tet in combination with DRL began to downregulate bcr/abl mRNA and P(210) BCR/ABL expression of K562 cells at 48 h and 72 h, respectively. It is concluded that tetrandrine in combination with Droloxifen can downregulate the expression of bcr/abl mRNA and P(210) BCR/ABL protein and the combination may be involved in the mechanism underlying the reverse effects on multidrug resistance in leukemia.
Chen
Bao-An
BA
Department of Hematology, Zhongda Hospital, Sourtheast University, Nanjing 210009, China. bachen@seu.edu.cn
Qian
Xi-Jun
XJ
Cheng
Jian
J
Gao
Feng
F
D000970:Antineoplastic Agents / Q000494:pharmacology; D044182:Benzylisoquinolines / Q000494:pharmacology*; D015153:Blotting, Western; D015536:Down-Regulation / Q000187:drug effects; D004357:Drug Synergism; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis* / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D020014:K562 Cells; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D044182:Benzylisoquinolines; D012333:RNA, Messenger; D013629:Tamoxifen; C038345:droloxifene; C009438:tetrandrine; D016044:Fusion Proteins, bcr-abl